Case Report

Vaping Is Not Safe: A Case of Acute Eosinophilic Pneumonia following Cannabis Vapor Inhalation

Daniel Antwi-Amoabeng and Raheel Islam

Department of Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA

Correspondence should be addressed to Daniel Antwi-Amoabeng; dantwiamoabeng@unr.edu

Received 8 September 2019; Accepted 29 November 2019; Published 27 January 2020

Academic Editor: Mortens Dahl

Copyright © 2020 Daniel Antwi-Amoabeng and Raheel Islam. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is a well-established association between inhalational exposures and acute eosinophilic pneumonia (AEP). The most reported exposure is cigarette smoking. Here, we present a case of progressive shortness of breath and nonproductive cough in a college student with no significant medical history, approximately 10 days after inhaling cannabis aerosols on two separate occasions. He was started on empiric antibiotics and bronchodilators without improvement. He was diagnosed with AEP based on peripheral eosinophilia and high-resolution CT image results. He made rapid recovery on intravenous glucocorticoids. Vaping has gained popularity among young adults mainly due to the perception that it is a safe alternative to smoking. This case shows that there may be a false sense of security with vaping. Vaping poses a yet-to-be quantified public health threat, which requires further studies.

1. Introduction

Acute eosinophilic pneumonia (AEP) is a rare cause of acute hypoxic respiratory failure. The exact pathophysiology is unknown, but it is thought to involve activation of the inflammation cascade resulting in recruitment of inflammatory cells predominantly, eosinophils to the lung parenchyma [1]. There have been reports associating this disease entity with exposure to drugs, dust, and cigarette smoking [2–6]. It generally occurs in men aged 20–30 years [7]. Patients present with nonspecific symptoms typical of community acquired pneumonia, and initial management is often focused on antibiotic therapy. Acute hypoxic respiratory failure, in an otherwise healthy young adult, can present a diagnostic challenge. Here, we present a case of acute eosinophilic pneumonia in a young male following cannabis inhalation.

2. Case Report

A 20-year-old male college student presented with three-week history of nonproductive cough, dyspnea, and wheezing. He was seen in the primary care office two weeks earlier and was started on albuterol and inhaled corticosteroids. He did not receive antibiotics. His symptoms briefly improved but he became more fatigued and, a week later, even more short of breath. He presented to the urgent care clinic and was found to be hypoxic with oxygen saturation of 83% on room air.

The patient’s roommate had mild upper respiratory tract symptoms a few days prior to the onset of the patient’s symptoms. The patient did not have fever, chills, headaches, myalgias or chest pain. Nor did he report engaging in risky sexual behavior or recent exotic travel. He denied cigarette smoking but admitted to smoking marijuana a few times a month. He had vaped marijuana on two separate occasions prior to symptom onset. He had a history of allergic rhinitis and took antihistamines as needed. His father had childhood asthma; and there was no other significant family history. The patient was allergic to penicillin.

On admission, he was afebrile, blood pressure was normal, but he was tachycardic. He was taking 29 breaths per minute and needed 3 liters per minute (LPM) of oxygen by nasal canula to maintain an oxygen saturation of 89%. He appeared tired, but his breathing was unlabored. He had scattered wheezes on lung auscultation. Chest X-ray showed increased pulmonary markings and possible multi-lobar pneumonia (Figure 1).
Complete metabolic panel was normal. WBC count was 35,000/µL, neutrophil 20.7%, eosinophil 64.9% (21.77 K/µL). His serum IgE was 823 kU/L. Tests for influenza A and B were negative. There was concern for community acquired pneumonia and he was started on Azithromycin and Ceftriaxone on admission but discontinued on the following day. We also considered allergic asthma, Allergic Bronchopulmonary Aspergillosis (ABPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), and other hypereosinophilic syndromes as potential etiologies for the patient’s symptoms.

He received nebulized bronchodilator treatment and oral Prednisone on admission, but his oxygen requirement had not improved on the next day. He needed 7 liters per minute oxygen via face mask to maintain oxygen saturation of 92%. In consultation with a Pulmonologist, antibiotics were discontinued due to strong suspicion of AEP on day one of hospitalization. High resolution CT of chest showed multifocal ill-defined ground glass opacities throughout both lungs, concerning for multifocal pneumonitis (Figure 2). The patient was started on Methylprednisolone 125 mg every eight hours, with rapid improvement in the eosinophilia and his respiratory status. A decision was made not to perform a bronchoalveolar lavage (BAL), because of his rapid response to corticosteroids and continued improvement in supplemental oxygen requirements. He was discharged home two days later with 2 LPM supplemental oxygen, steroid taper, and advised to desist from using marijuana in any form. Blood and sputum cultures remained negative on the day of discharge. Test for infectious etiology including HIV, Coccidioides, Aspergillus, Strongyloides antibody were all negative.

On follow-up, six days post discharge, he no longer required supplemental oxygen and had returned to his usual activity such as going to the gym. He saw an allergist three months later due to concern for ABPA. IgE had improved to 689 kU/L. Test for Anti-myeloperoxidase antibody, Protease 3b (PR3) antibody, antinuclear antibodies (ANA), Antineutrophil cytoplasmic antibody (ANCA) were all negative. Based on these results, EGPA was an unlikely etiology of his dyspnea and peripheral eosinophilia. He showed increased allergic response to cat dander, mites, Aspergillus fumigatus, and to tree and grass allergens. Tryptase assay returned normal result which, made a diagnosis of eosinophilic leukemia less likely. BAL at that time showed 75% eosinophils and the transbronchial biopsy showed pulmonary eosinophilia (Loeffler’s type). Further, there were no parasites; no fungi; no granulomas; no organizing pneumonia; and no malignant cells in the BAL and biopsy samples. Bone marrow biopsy did not show increased blast cells, and no monotypic blast cell increase was observed either. The patient stopped using the vaping device. Unfortunately, he returned to smoking marijuana (via combustion) a few times with return of dyspnea and he needed prolonged steroid therapy.

3. Discussion

AEP is an uncommon cause of acute hypoxic respiratory failure and is associated with smoking cigarettes and/or cannabis [4, 8, 9]. In the present case, we report acute eosinophilic pneumonia in a patient following inhalation of aerosolized cannabis a few days prior to symptom onset. Further, we excluded infectious etiology as detailed above. ABPA was excluded by negative Aspergillus skin test, radiographic findings, and biopsy analysis. We also excluded acute eosinophilic pneumonia by demonstrating normal bone marrow, a normal Tryptase assay, and the absence of anemia and thrombocytopenia on venous blood samples. He was not on any medications associated with drug reactions and eosinophilia. He did not have serologic or biopsy features typical of EGPA. He did have a history of atopy and rhinitis, which made allergic/atopic etiology a strong consideration, but his pulmonary infiltrates suggested a more diffuse etiology affecting the lung parenchyma. Since the patient had not changed the frequency or intensity of his marijuana smoking, we concluded that the recent initiation of cannabis vapor inhalation (vaping) was the precipitating factor in this case.

There is no consensus on the diagnostic criteria for AEP. The modified Philit Criteria [1, 10, 11] used to diagnose AEP include: (1) Acute respiratory illness of less than 1-month duration. (2) Pulmonary infiltrates on chest imaging. (3) BAL with eosinophils >25% or eosinophilic pneumonia on lung biopsy. (4) Absence of other eosinophilic pulmonary diseases, including eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndromes; and allergic bronchopulmonary aspergillosis. Our patient met each of the diagnostic criteria for AEP. He had rapid improvement in clinical, laboratory and imaging findings after initiation of steroids; in line with prior reports [12, 13]. It appears re-exposure to precipitants in the immediate convalescence period that resulted in re-occurrence of symptoms and radiologic findings [13]. Although recurrence of AEP once a patient resumes smoking is not common, there have been some reports [14]. Our patient stopped vaping marijuana, but he returned to smoking marijuana a few times a week with recurrence of dyspnea and cough. Of critical note, his disease had progressed to chronic eosinophilic pneumonia on six-months follow-up. He appears to now depend on steroids as his symptoms came back when he stopped taking steroids.

The patient presented with features uncommon in AEP. First, he did not have a fever. Fever is often reported but not always present in those with AEP [4, 15, 16]. The modified Philit criteria removes “febrile illness” as a criterion. Thus, the
absence of fever does not invalidate a diagnosis of AEP in this patient. Second, he had increased peripheral eosinophilia. Peripheral eosinophilia is not a prominent feature of AEP, but when present, it is associated with milder symptoms and may be a good prognostic feature useful in stratifying patients on initial presentation [17].

History of atopy may not be relevant to developing AEP, but total IgE levels and peripheral eosinophilia may correlate with disease severity [18]. The patient’s serum IgE levels were markedly elevated when he initially presented, as in another reported case, [8] pointing to a role of type 1 hypersensitivity in the etiology of AEP. The levels were still high on follow-up but were lower than initial levels. His symptoms were resolved at that time as he was on steroids. E-cigarettes or vaporizers have become very popular. They are marketed as a substitute for cigarettes, and have been shown to be more effective for smoking cessation than traditional nicotine replacement therapy among adults [19]. These vaporizers have been adapted to deliver liquid and oil forms of tetrahydrocannabinol (THC) and cannabidiol (CBD) with a myriad of flavoring options [20]. The prevalence of cannabis vaping is speculative, but the act is perceived as innocuous, which may attract even the more cautious users. Youth describe the contents of vaping oils as harmless "water vapor," which may be “good” for them [21].

The vapor from these vaping devices may contain particulate matter, as well as chemicals such as carbonyls, volatile organic compounds, and toxic metals, which have been linked to dyspnea, cough, upper airways irritation, asthma, pneumonia and lung cancer [22, 23]. Inhaling aerosols has been shown to increase airway resistance and decrease FEV1 in healthy nonsmokers [24].

Flavored vaping e-liquids have been found to contain high levels of diacetyl, [25] a substance known to be strongly associated with bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings [26]. Diacetyl has been found in many flavored products including vaping liquids [27]. We suggest that the flavoring components, or components of the cannabis product, present an antigenic challenge to alveolar macrophages with exaggerated secondary response on subsequent exposure. The Centers for Disease Control and Prevention (CDC) has identified a new pulmonary pathology in patients who presented with insidious onset of dyspnea after recent use of THC-containing vaping products: e-cigarette, or vaping, product use associated lung injury (EVALI). In a recent update the CDC reports that Vitamin E acetate, used as a thickening agent, has been identified in BAL samples from several patients diagnosed with EVALI. THC was also identified in most of the samples from patients. In the same update, CDC reported that EVALI occurred mostly
in males ranging in age from 13 to 78 [28]. It is impossible to determine the underlying pathophysiology of AEP in our patient. Certainly, further studies are required to outline the disease mechanisms involved in EV ALI. For now, our best defense is public health education to discourage use of vaping products especially. Limiting vaping liquid flavors and the use of Vitamin E acetate in vaping products may help curb the popularity of vaping among youth and young adults and help avert a looming public health crisis of severe pulmonary illness in those who vape.

4. Conclusion

There have been recent reported cases of pulmonary illness associated with vaping. There have been prior reports of AEP associated with smoking marijuana. This case represents yet another example of the harms of vaping, which had, until recently, been unknown to the general public. We are unable to state if the specific THC product vaped by our patient contained vitamin E acetate, diacetyl or other potentially harmful additives. We have however, established a correlation between vaping cannabis aerosols and the onset of acute eosinophilic pneumonia in this patient. Acute hypoxic respiratory failure in an otherwise healthy young adult can present a diagnostic challenge, but peripheral eosinophilia, although an uncommon feature, and recent inhalational exposures should present early clues to suspect AEP. Prompt initiation of steroids is essential with rapid and complete resolution of symptoms, but symptoms may reoccur if the patient resumes exposure behavior during the convalescent period. Vaping behavior is very common among the youth and poses a preventable risk for debilitating pulmonary disease. Providers should discourage vaping in young nonsmokers and advise smokers to not take up vaping as a smoking cessation tool. They should also stick with conventional smoking cessation tools for smokers who wish to stop smoking cigarettes.

Disclosure

A poster version of this case was presented at the annual Resident/Fellows Research Day at the University of Nevada, Reno School of Medicine on May 30th, 2019 in Reno, NV, USA.

Conflicts of Interest

The authors report no conflicts of interest.

References

[1] F. De Giacomi, R. Vassallo, E. S. Yi, and J. H. Ryu, “Acute eosinophilic pneumonia. Causes, diagnosis, and management,” American Journal of Respiratory and Critical Care Medicine, vol. 197, no. 6, pp. 728–736, 2018.

[2] E. Anan, R. Shirai, N. Kai et al., “Acute eosinophilic pneumonia caused by several drugs including ibuprofen,” Nihon Kokyuki Gakkai Zasshi, vol. 47, no. 5, pp. 443–447, 2009.

[3] L. Fourmont, M. Revol, E. Polard et al., “Acute eosinophilic pneumonia following artenimol-piperaquine exposure,” Journal of Travel Medicine, vol. 24, no. 5, 2017.

[4] A. Natarajan, P. Shah, A. E. Mirrakhimov, and N. Hussain, “Eosinophilic pneumonia associated with concomitant cigarette and marijuana smoking,” BMJ Case Reports, vol. 2013, no. 1, 2013.

[5] W. N. Rom, M. Weiden, R. Garcia et al., “Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 6, pp. 797–800, 2002.

[6] H. Uchiyama, T. Suda, Y. Nakamura et al., “Alterations in smoking habits are associated with acute eosinophilic pneumonia,” Chest, vol. 133, no. 5, pp. 1174–1180, 2008.

[7] J. N. Allen and W. B. Davis, “Eosinophilic lung diseases,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 5, pp. 1423–1438, 1994.

[8] M. Diaz-Abad, L. Malone, L. Ali, E. M. Pickering, and A. Sachdeva, “Acute eosinophilic pneumonia triggered by secondhand cigarette smoke exposure in an elderly man,” Monaldi Archives for Chest Disease, vol. 89, no. 1, 2019.

[9] P. D. Liebling and S. Siu, “A novel cause of eosinophilic pneumonia: recreational marijuana exposure,” Journal of Bronchology & Interventional Pulmonology, vol. 20, no. 2, pp. 183–185, 2013.

[10] F. Philit, E. Etienne-Mastroianni, A. Parrot, C. Guerin, D. Robert, and J. E. Cordier, “Idiopathic acute eosinophilic pneumonia: a study of 22 patients,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 9, pp. 1235–1239, 2002.

[11] C. K. Rhee, K. H. Min, N. Y. Yim et al., “Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia,” European Respiratory Journal, vol. 41, no. 2, pp. 402–409, 2013.

[12] S. Y. Park, J. H. Kim, M. J. Chung, C. H. Rhee, and S. J. Park, “Acute eosinophilic pneumonia and tracheitis associated with smoking,” American Journal of Respiratory and Critical Care Medicine, vol. 195, no. 12, pp. 1671–1672, 2017.

[13] H. Shintani, M. Fujimura, Y. Ishiura, and M. Noto, “A case of cigarette smoking-induced acute eosinophilic pneumonia showing tolerance,” Chest, vol. 117, no. 1, pp. 277–279, 2000.

[14] Y. Shiota, T. Kawai, H. Matsumoto et al., “Acute eosinophilic pneumonia following cigarette smoking,” Internal Medicine, vol. 39, no. 10, pp. 830–833, 2000.

[15] T. Kawamura, Y. Mochizuki, Y. Nakahara, T. Kimoto, and S. Watanabe, “A clinical study of 5 cases of acute eosinophilic pneumonia–the relationship between beginning to smoke and acute eosinophilic pneumonia,” Japanese Journal of Thoracic Disease, vol. 35, no. 11, pp. 1252–1258, 1997.

[16] K. Watanabe, M. Fujimura, K. Kasahara et al., “Acute eosinophilic pneumonia following cigarette smoking: a case report including cigarette-smoking challenge test,” Internal Medicine, vol. 41, no. 11, pp. 1016–1020, 2002.

[17] B. W. Jhun, S. J. Kim, K. Kim, and J. E. Lee, “Clinical implications of initial peripheral eosinophilia in acute eosinophilic pneumonia,” Respiratory Medicine, vol. 19, no. 7, pp. 1059–1065, 2014.

[18] T. Hattori, N. Hizawa, D. Takahashi et al., “Total serum IgE levels in eosinophilic lung diseases,” Arerugi, vol. 55, no. 6, pp. 647–654, 2006.

[19] P. Hajek, A. Phillips-Waller, D. Przulj et al., “A randomized trial of e-cigarettes versus nicotine-replacement therapy,” New England Journal of Medicine, vol. 380, no. 7, pp. 629–637, 2019.
Case Reports in Pulmonology

[20] CDC, "E-cigarette use among youth and young adults: a report of the of the surgeon general," 2016, https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/pdfs/2016_SGR_Chop_1_508.pdf.

[21] E. A. McDonald and P. M. Ling, "One of several “toys” for smoking: young adult experiences with electronic cigarettes in New York City," Tobacco Control, vol. 24, no. 6, pp. 588–593, 2015.

[22] S. Gaur and R. Agnihotri, "Health effects of trace metals in electronic cigarette aerosols—a systematic review," Biological Trace Element Research, vol. 188, no. 2, pp. 295–315, 2019.

[23] P. Olmedo, W. Goessler, S. Tanda et al., "Metal concentrations in e-cigarette liquid and aerosol samples: the contribution of metallic coils," Environmental Health Perspectives, vol. 126, no. 2, p. 027010, 2018.

[24] C. I. Vardavas, N. Anagnostopoulos, M. Kougias, V. Evangelopoulou, G. N. Connolly, and P. K. Behrakis, "Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide," Chest, vol. 141, no. 6, pp. 1400–1406, 2012.

[25] J. G. Allen, S. S. Flanigan, M. LeBlanc et al., "Flavoring chemicals in e-cigarettes: diacetyl, 2,3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes," Environmental Health Perspectives, vol. 124, no. 6, pp. 733–739, 2016.

[26] F. G. van Rooy, J. M. Rooyackers, M. Prokop, R. Houba, L. A. Smit, and D. J. Heederik, "Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings," American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 5, pp. 498–504, 2007.

[27] CDC. (n.d.), "Electronic cigarettes, what is the bottom line?" https://www.cdc.gov/tobacco/basic_information/e-cigarettes/pdfs/Electronic-Cigarettes-Infographic-p.pdf.

[28] CDC, “Outbreak of lung injury associated with the use of e-cigarette, or vaping, products,” 2019, https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html.